Telix Pharmaceutical/$TLX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Telix Pharmaceutical
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
- Ticker
- $TLX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,152
- Headquarters
- North Melbourne, Australia
- Website
- telixpharma.com
TLX Metrics
BasicAdvanced
$3.1B
95.40
$0.10
0.60
-
Price and volume
Market cap
$3.1B
Beta
0.6
52-week high
$13.11
52-week low
$6.28
Average daily volume
419K
Financial strength
Current ratio
2.014
Quick ratio
1.743
Long term debt to equity
1.157
Total debt to equity
1.189
Interest coverage (TTM)
3.69%
Profitability
EBITDA (TTM)
69.806
Gross margin (TTM)
47.57%
Net profit margin (TTM)
3.76%
Operating margin (TTM)
6.20%
Effective tax rate (TTM)
-16.24%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
2.71%
Return on equity (TTM)
7.37%
Valuation
Price to earnings (TTM)
95.402
Price to revenue (TTM)
3.493
Price to book
9.15
Price to tangible book (TTM)
-46.02
Price to free cash flow (TTM)
-66.486
Free cash flow yield (TTM)
-1.50%
Free cash flow per share (TTM)
-0.137
Growth
Revenue change (TTM)
33.49%
Earnings per share change (TTM)
174.82%
3-year revenue growth (CAGR)
53.38%
3-year earnings per share growth (CAGR)
-2.87%
What the Analysts think about TLX
Analyst ratings (Buy, Hold, Sell) for Telix Pharmaceutical stock.
Analyst projections of the future price of Telix Pharmaceutical stock.
Bulls say / Bears say
Third-quarter revenue rose 19% year on year, with Precision Medicine revenue up 30%, and Telix reaffirmed full-year revenue guidance of US$950–970 million. That points to continued demand for its commercial products. (GlobeNewswire)
The FDA approved Pixclara for glioma imaging, making it the first approved imaging agent for this use in the US, and Telix reported that first commercial doses were given in September. BiPASS also completed enrolment, with an FDA-supported route towards an application that could broaden the prostate-imaging market. (GlobeNewswire)
The proposed ITM merger could add isotope production and manufacturing capabilities alongside a broader therapeutic pipeline. This may strengthen Telix’s supply chain and give it more ways to develop and commercialise radiopharmaceuticals. (SEC)
Commercial revenue remains concentrated in prostate-cancer imaging: Precision Medicine generated US$201 million of Q3’s US$245 million revenue, mainly from Illuccix and Gozellix. Group revenue was also 1% lower than in Q2, so continued growth depends heavily on a narrow product area. (GlobeNewswire)
Investment costs are rising: first-half R&D spending increased to US$124 million from US$82 million, while the manufacturing segment’s adjusted EBITDA loss widened to US$23 million from US$13 million. The US$38 million first-half profit also included a US$40 million Regeneron payment, so it overstates recurring earnings. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
TLX Financial Performance
Revenues and expenses
TLX Earnings Performance
Company profitability
Upcoming events
No upcoming events
TLX News
AllArticlesVideos
Funds containing TLX
AllUSDEURGBP
Fund name | Fund size | $TLX weighting |
|---|---|---|
Vanguard FTSE Developed Asia Pacific ex Japan$VDPX | $2B | 0.06% |
Vanguard FTSE Developed Asia Pacific ex Japan€VAPX | $2B | 0.06% |
Vanguard FTSE Developed Asia Pacific ex Japan$VAPU | $1B | 0.06% |
Vanguard FTSE Developed Asia Pacific ex Japan£VAPX | $2B | 0.06% |
Vanguard FTSE Developed Asia Pacific ex Japan£VDPG | $1B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.